Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line

Molecular Medicine Reports

Volumn 3, Issue 2, 2010, Pages 333-339

  Yerlikaya, Azmi ^a   Okur, Emrah ^a   Şeker, Semih ^a   Erin, Nuray ^b  

^a DUMLUPINAR UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Bortezomib; Heat shock protein 70; KNK 437; Proteasome; Quercetin; Schisandrin B

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; QUERCETIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DETERMINATION; GROWTH INHIBITION; IC 50; MELANOMA; MOUSE; NONHUMAN;

EID: 77950793297     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr_000000262     Document Type: Article

References (40)

1. Ding Q, Cecarini V and Keller JN: Interplay between protein synthesis and degradation in the CN S: physiological and pathological implications. Trends Neurosci 30: 31-36, 2007.
2. Goldberg AL : Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899, 2003.
3. Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem 67: 425-479, 1998.
4. Hilt W and Wolf DH: Proteasomes: destruction as a programme. Trends Biochem Sci 21: 96-102, 1996.
5. Voges D, Zwickl P and Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68: 1015-1068, 1999.
6. Kisselev AF, Akopian TN and Goldberg AL : Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes. J Biol Chem 273: 1982-1989, 1998.
7. N Nussbaum AK, Dick TP, Keilholz W, Schirle M, Stevanovic S, Dietz K, Heinemeyer W, Groll M, Wolf DH, Huber R, Rammensee HG and Schild H: Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc Natl Acad Sci USA 95: 12504-12509, 1998.
8. Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82: 373-428, 2002.
9. Zwickl P, Voges D and Baumeister W: The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc Lond B Biol Sci 354: 1501-1511, 1999. (Pubitemid 29464081)
10. Murakami Y, Matsufuji S, Kameji T, Hayashi S, Igarashi K, Tamura T, Tanaka, K and Ichihara A: Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination. Nature 360: 597-599, 1992.
11. Pagano M: Cell cycle regulation by the ubiquitin pathway. FASEB J 11: 1067-1075, 1997.
12. He H, Qi XM, Grossmann J and Distelhorst CW: c-Fos degradation by the proteasome. An early, Bcl-2-regulated step in apoptosis. J Biol Chem 273: 25015-25019, 1998.
13. Yerlikaya A and Stanley BA: S-adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination. J Biol Chem 279: 12469-12478, 2004.
14. Pickart CM and Eddins MJ: Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695: 55-72, 2004.
15. Hershko A, Ciechanover A and Varshavsky A: Basic Medical Research Award. The ubiquitin system. Nat Med 6: 1073-1081, 2000.
16. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK and Varshavsky A: A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 243: 1576-1583, 1989.
17. Jentsch S: The ubiquitin-conjugation system. Annu Rev Genet 26: 179-207, 1992.
18. Hershko A, Ciechanover A, Heller H, Haas AL and Rose IA : Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA 77: 1783-1786, 1980.
19. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771, 1994.
20. Patnaik A, Chau V and Wills JW: Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci USA 97: 13069-13074, 2000.
21. Yerlikaya A, Kimball SR and Stanley BA: Phosphorylation of eIF2a in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI ) kinase. Biochem J 412: 579-588, 2008.
22. Hershko A: Ubiquitin-mediated protein degradation. J Biol Chem 263: 15237-15240, 1988.
23. Davie JR and Murphy LC : Level of ubiquitinated histone H2B in chromatin is coupled to ongoing transcription. Biochemistry 29: 4752-4757, 1990.
24. Kim D, Kim SH and Li GC: Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression. Biochem Biophys Res Commun 254: 264-268, 1999.
25. Jones EL , Zhao MJ, Stevenson MA and Calderwood SK: The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer. Int J Hyperthermia 20: 835-849, 2004.
26. Samali A and Cotter TG: Heat shock proteins increase resistance to apoptosis. Exp Cell Res 223: 163-170, 1996.
27. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU , Gribben JG, Newland AC and Jia L: Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 112: 3835-3846, 2008.
28. Adams J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5: 417-421, 2004.
29. Burger AM and Seth AK: The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer 40: 2217-2229, 2004.
30. Chauhan D, Hideshima T, Mitsiades C, Richardson P and Anderson KC: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4: 686-692, 2005.
31. Voortman J, Checinska A and Giaccone G: The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells. Mol Cancer 6: 73, 2007.
32. Yerlikaya A and Erin N: Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade. Int J Mol Med 22: 817-823, 2008.
33. Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94: 855-860, 1997.
34. Rodriguez J, Yanez J, Vicente V, Alcaraz M, Benavente-Garcia O, Castillo J, Lorente J and Lozano JA: Effects of several flavonoids on the growth of B16F10 and SK-MEL -1 melanoma cell lines: relationship between structure and activity. Melanoma Res 12: 99-107, 2002.
35. Kubo I, Nitoda T and Nihei K: Effects of quercetin on mushroom tyrosinase and B16-F10 melanoma cells. Molecules 12: 1045-1056, 2007.
36. Yokota S, Kitahara M and Nagata K: Benzylidene lactam compound, KNK437, a novel inhibitor of acquisition of thermo-tolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res 60: 2942-2948, 2000.
37. Wu YF, Cao MF, Gao YP, Chen F, Wang T, Zumbika EP and Qian KX: Down-modulation of heat shock protein 70 and up-modulation of caspase-3 during schisandrin B-induced apoptosis in human hepatoma SMMC-7721 cells. World J Gastroenterol 10: 2944-2948, 2004.
38. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.
39. Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC , Richardson PG, Singer JW and Anderson KC: Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene 24: 3121-3129, 2005.
40. Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T and Anderson KC: Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 63: 6174-6177, 2003.